Auszug
Von den Diuretika werden hauptsächlich Schleifendiuretika und Thiazide verordnet. Aldosteronantagonisten folgen mit deutlichem Abstand. Schleifendiuretika sind weiterhin und mit steigender Tendenz die dominierende Gruppe der Diuretika und machten 2006 fast 60% der verordneten Tagesdosen dieser Gruppe aus. Der Verordnungsumfang von Thiaziden als Monopräparate ist seit einigen Jahren stabil, während sich der seit 10 Jahren zu beobachtenden Rückgang ihrer Kombinationen mit kaliumsparenden Diuretika weiter fortgesetzt hat. In ähnlicher Weise hat der Einsatz von Spironolacton in Kombination mit Furosemid abgenommen, während es als Monopräparat deutlich häufiger eingesetzt wurde.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Chobanian AV, Bakris GL, Black HR, Cushman WC et al (2003):The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289: 2560–2571.
Cosin J, Diez J, TORIC investigators (2003): Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4: 507–513.
Düsing R, Piesche L (1990): Second line therapy of congestive heart failure with torasemide. Prog Pharmacol Clin Pharmacol 8: 105–120.
Gentilini P, Laffi G, La Villa G, Carloni V, Foschi M, Romanelli RG, Marra F (1993): Torasemide in the treatment of patients with cirrhosis and ascites. Cardiovasc Drugs Ther 7(Suppl 1): 81–85.
Greger R (1995): Loop Diuretics. In: Greger R, Knauf H, Mutschler, E (eds): Handbook of Experimental Pharmacology: Diuretics, Vol 117. Springer-Verlag, Berlin, pp 221–274.
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004): Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543–551.
Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM et al (2001): Open label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 111: 513–520.
Noe LL, Vreeland MG, Pezzella SM, Trotter JP (1999): A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure. Clin Ther 21: 854–866.
Oßwald H, Vallon V, Luippold G, Gleiter CH (2004): Diuretika — Physiologie, Pharmakologie und klinische Anwendungen. Wissenschaftliche Verlagsgesellschaft, Stuttgart
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999): The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709–717.
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003): Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321.
Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS (2003): Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289: 2534–2544.
Scheen AJ, Vancrombreucq JC, Delarge J, Luyckx AS (1986): Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol 31 (Suppl): 35–42.
Spannheimer A, Goertz A, Dreckmann-Behrendt B (1998): Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int J Clin Pract 52: 467–471.
Stauch M, Stiehl L (1990): Controlled, double-blind clinical trial on the efficacy and tolerance of torasemide in comparison with furosemide in patients with congestive heart failure — amulticenter study. Prog Pharmacol Clin Pharmacol 8: 121–126.
Stroupe KT, Forthofer MM, Brater DC, Murray MD (2000): Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 17: 429–440.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2003). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997.
Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC (1995): Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 57: 601–609.
Wilcox CS (2002): New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 13: 798–805.
Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL (2006): Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48: 219–224.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Osswald, H., Mühlbauer, B. (2008). Diuretika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_25
Download citation
DOI: https://doi.org/10.1007/978-3-540-72548-0_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-72547-3
Online ISBN: 978-3-540-72548-0
eBook Packages: Medicine (German Language)